Recombinant Human LILRB1/CD85j/ILT2 His Avi-tag Protein, CF

When Human LILRB1/CD85j/ILT2 Antibody (MAB20172) is immobilized at 0.2 µg/mL (100 µL/well), Biotinylated Recombinant Human LILRB1/CD85j/ILT2 His-tag Avi-tag Protein (Catalog # AVI8989) binds with an ED50 of 0.600-9.00 ng/mL.

2 μg/lane of Biotinylated Recombinant Human LILRB1/CD85j/ILT2 His-tag Avi-tag Protein (Catalog # AVI8989) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 70-80 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LILRB1/CD85j/ILT2 His Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Human LILRB1/CD85j/ILT2 Antibody (Catalog # MAB20172) is immobilized at 0.2 µg/mL (100 µL/well), Biotinylated Recombinant Human LILRB1/CD85j/ILT2 His-tag Avi-tag (Catalog # AVI8989) binds with an ED₅₀ of 0.600-9.00 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human LILRB1/CD85j/ILT2 protein
  

  Human LILRB1/CD85j/ILT2 (Gly24-Arg457) Accession # Q8NHL6.1	6-His tag	Avi-tag
  N-terminus		C-terminus

• Accession #: Q8NHL6.1
• N-terminal Sequence: Gly24
• Structure / Form: Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 50 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 70-80 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LILRB1/CD85j/ILT2 His Avi-tag Protein, CF

• CD85 antigen-like family member J
• CD85j antigen
• CD85j
• Ig-like transcript 2
• ILT2
• ILT-2
• ILT2FLJ37515
• Immunoglobulin-like transcript 2
• leukocyte Ig-like receptor-1
• Leukocyte immunoglobulin-like receptor 1
• leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform
• leukocyte immunoglobulin-like receptor subfamily B member 1
• leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains)
• LILRB1
• LIR1
• LIR1LIR-1MIR-7CD85MIR7CD85 antigen
• member 1
• MIR7
• Monocyte/macrophage immunoglobulin-like receptor 7

Background

LILRB1, also known as CD85j and ILT2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family (1). Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs (2). Alternative splicing generates an additional isoform that lacks the transmembrane and cytoplasmic regions (3). LILRB1 is expressed on the surface of B cells and monocytes, as well as subsets of NK cells, memory/effector CD8+ T cells, gamma δ T cells, and monocyte-derived dendritic cells (3-7). LILRB1 binds to MHC-I as well as non-classical MHC-I molecules (e.g. HLA-F, HLA-G, and HLA-B27) and the MHC-I mimetic UL18 encoded by cytomegalovirus (3, 5, 8-10). R&D Systems in-house testing indicates that LILRB1 also binds to Angiopoietin-like 7. Ligation of LILRB1 inhibits the antigen induced proliferation and activation of CD8+ T cells, CD4+ T cells, NK cells, and gamma δ T cells (3, 4, 11-13). On dendritic cells, ligation inhibits the production of IL-10, IL-12p70, and TGF-beta and protects from Fas-mediated apoptosis (7). Our Avi-tag Biotinylated human LILRB1 His-tag protein features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
2. Samaridis, J. and M. Colonna (1997) Eur. J. Immunol. 27:660.
3. Colonna, M. et al. (1997) J. Exp. Med. 186:1809.
4. Harly, C. et al. (2011) Blood 117:2864.
5. Cosman, D. et al. (1997) Immunity 7:273.
6. Young, N.T. et al. (2001) J. Immunol. 166:3933.
7. Young, N.T. et al. (2008) Blood 111:3090.
8. Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
9. Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. USA 100:8856.
10. Allen, R.L. et al. (2001) J. Immunol. 167:5543.
11. Ince, M.N. et al. (2004) Immunology 112:531.
12. Saverino, D. et al. (2000) J. Immunol. 165:3742.
13. Saverino, D. et al. (2002) J. Immunol. 168:207.

Bioinformatics

• Uniprot:
  • Q8NHL6.1()